Literature DB >> 23636059

Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors.

Florence Anne Castelli1, Natacha Szely, Alexis Olivain, Nicoletta Casartelli, Caroline Grygar, Aurélie Schneider, Aurore Besse, Yves Levy, Olivier Schwartz, Bernard Maillère.   

Abstract

The Agence National de Recherche sur le SIDA et les hepatitis Lipo5 vaccine is composed by five long fragments of HIV proteins and was recently shown to induce in seronegative volunteers a CD4 T cell response largely dominated by the G2 fragment. To understand this response profile, we submitted the five HIV fragments to HLA-DR-binding assays and evaluated the frequency of naive Lipo5-specific CD4 T lymphocytes in the blood of 22 healthy individuals. We enumerated the Lipo5-specific T cell lines induced in vitro by weekly rounds of specific stimulation. Four peptides and hence not only G2 exhibited a broad specificity for HLA-DR molecules. In contrast, most of the T cell lines specific for Lipo5 reacted with G2, revealing a G2-specific T cell repertoire superior to 2 cells per million, whereas it is close to 0.4 for the other peptides. We also found good cross-reactivity of all the peptides with clade B and C variants and that G2 and P1 are able to recruit T cells that recognize HIV-infected cells. We therefore mainly observed very good concordance between the frequency to individual Lipo5 peptides among vaccinees in a large-scale vaccine trial and the distribution of peptide specificity of the in vitro induced T cell lines. These findings underline the role of the size of the epitope-specific naive repertoire in shaping the CD4 T cell response after vaccination and highlight the value of evaluating the naive repertoire to predict vaccine immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636059     DOI: 10.4049/jimmunol.1300145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Authors:  Sylvain Meunier; Catherine Menier; Elodie Marcon; Sébastien Lacroix-Desmazes; Bernard Maillère
Journal:  Blood Adv       Date:  2017-09-25

2.  DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.

Authors:  Madhura Mukhopadhyay; Moran Galperin; Mandar Patgaonkar; Sandhya Vasan; David D Ho; Alexandre Nouël; Mathieu Claireaux; Daniela Benati; Olivier Lambotte; Yaoxing Huang; Lisa A Chakrabarti
Journal:  J Immunol       Date:  2017-10-09       Impact factor: 5.422

3.  Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.

Authors:  Moustafa Hamze; Sylvain Meunier; Anette Karle; Abdelaziz Gdoura; Amélie Goudet; Natacha Szely; Marc Pallardy; Franck Carbonnel; Sebastian Spindeldreher; Xavier Mariette; Corinne Miceli-Richard; Bernard Maillère
Journal:  Front Immunol       Date:  2017-05-05       Impact factor: 7.561

Review 4.  Drug and Chemical Allergy: A Role for a Specific Naive T-Cell Repertoire?

Authors:  Rami Bechara; Alexia Feray; Marc Pallardy
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

5.  Characterization of Proinsulin T Cell Epitopes Restricted by Type 1 Diabetes-Associated HLA Class II Molecules.

Authors:  Emmi-Leena Ihantola; Henna Ilmonen; Anssi Kailaanmäki; Marja Rytkönen-Nissinen; Aurélien Azam; Bernard Maillère; Cecilia S Lindestam Arlehamn; Alessandro Sette; Keshav Motwani; Howard R Seay; Todd M Brusko; Mikael Knip; Riitta Veijola; Jorma Toppari; Jorma Ilonen; Tuure Kinnunen
Journal:  J Immunol       Date:  2020-03-30       Impact factor: 5.426

6.  The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles.

Authors:  Catherine J Reynolds; Claire Jones; Christoph J Blohmke; Thomas C Darton; Amelie Goudet; Ruhena Sergeant; Bernard Maillere; Andrew J Pollard; Daniel M Altmann; Rosemary J Boyton
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

7.  Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.

Authors:  Sebastian Spindeldreher; Bernard Maillère; Evelyne Correia; Maxime Tenon; Anette Karle; Philip Jarvis; Frank Kolbinger
Journal:  Dermatol Ther (Heidelb)       Date:  2018-02-01

Review 8.  Specificity of the T Cell Response to Protein Biopharmaceuticals.

Authors:  Sylvain Meunier; Marie de Bourayne; Moustafa Hamze; Aurélien Azam; Evelyne Correia; Catherine Menier; Bernard Maillère
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

9.  High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes.

Authors:  Fanny Onodi; Chahrazed Maherzi-Mechalikh; Alice Mougel; Nadine Ben Hamouda; Charlotte Taboas; Fabien Gueugnon; Thi Tran; Herve Nozach; Elodie Marcon; Alain Gey; Magali Terme; Ahmed Bouzidi; Bernard Maillere; Jérôme Kerzerho; Eric Tartour; Corinne Tanchot
Journal:  Front Oncol       Date:  2018-11-13       Impact factor: 6.244

10.  Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination.

Authors:  Mathieu Surenaud; Monica Montes; Cecilia S Lindestam Arlehamn; Alessandro Sette; Jacques Banchereau; Karolina Palucka; Jean-Daniel Lelièvre; Christine Lacabaratz; Yves Lévy
Journal:  PLoS Pathog       Date:  2019-09-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.